TY - JOUR
T1 - Cost evaluation of dried blood spot home sampling as compared to conventional sampling for therapeutic drug monitoring in children
AU - Martial, Lisa C.
AU - Aarnoutse, Rob E.
AU - Schreuder, Michiel F.
AU - Henriet, Stefanie S.
AU - Brüggemann, Roger J.M.
AU - Joor, Manuela A.
N1 - Publisher Copyright:
© 2016 Martial et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2016/12
Y1 - 2016/12
N2 - Dried blood spot (DBS) sampling for the purpose of therapeutic drug monitoring can be an attractive alternative for conventional blood sampling, especially in children. This study aimed to compare all costs involved in conventional sampling versus DBS home sampling in two pediatric populations: renal transplant patients and hemato-oncology patients. Total costs were computed from a societal perspective by adding up healthcare cost, patient related costs and costs related to loss of productivity of the caregiver. Switching to DBS home sampling was associated with a cost reduction of 43% for hemato-oncology patients (€277 to €158) and 61% for nephrology patients (€259 to €102) from a societal perspective (total costs) per blood draw. From a healthcare perspective, costs reduced with 7% for hemato-oncology patients and with 21% for nephrology patients. Total savings depend on the number of hospital visits that can be avoided by using home sampling instead of conventional sampling.
AB - Dried blood spot (DBS) sampling for the purpose of therapeutic drug monitoring can be an attractive alternative for conventional blood sampling, especially in children. This study aimed to compare all costs involved in conventional sampling versus DBS home sampling in two pediatric populations: renal transplant patients and hemato-oncology patients. Total costs were computed from a societal perspective by adding up healthcare cost, patient related costs and costs related to loss of productivity of the caregiver. Switching to DBS home sampling was associated with a cost reduction of 43% for hemato-oncology patients (€277 to €158) and 61% for nephrology patients (€259 to €102) from a societal perspective (total costs) per blood draw. From a healthcare perspective, costs reduced with 7% for hemato-oncology patients and with 21% for nephrology patients. Total savings depend on the number of hospital visits that can be avoided by using home sampling instead of conventional sampling.
UR - http://www.scopus.com/inward/record.url?scp=85005949898&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0167433
DO - 10.1371/journal.pone.0167433
M3 - Article
C2 - 27941974
AN - SCOPUS:85005949898
SN - 1932-6203
VL - 11
JO - PLoS ONE
JF - PLoS ONE
IS - 12
M1 - e0167433
ER -